156,076 Shares in Chimerix, Inc. (NASDAQ:CMRX) Purchased by Marshall Wace LLP

Marshall Wace LLP acquired a new position in shares of Chimerix, Inc. (NASDAQ:CMRX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 156,076 shares of the biopharmaceutical company’s stock, valued at approximately $137,000.

Other institutional investors have also added to or reduced their stakes in the company. Marquette Asset Management LLC raised its holdings in shares of Chimerix by 24.3% in the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 22,709 shares in the last quarter. Koshinski Asset Management Inc. purchased a new stake in shares of Chimerix in the 1st quarter valued at about $42,000. Finally, Acadian Asset Management LLC raised its holdings in shares of Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company’s stock valued at $2,304,000 after acquiring an additional 291,981 shares in the last quarter. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on CMRX. Wedbush reiterated an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research report on Tuesday, August 13th. StockNews.com upgraded Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research report on Wednesday, August 14th.

Chimerix Price Performance

CMRX opened at $0.89 on Monday. The stock’s 50 day simple moving average is $0.90 and its 200 day simple moving average is $0.92. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $1.30. The firm has a market cap of $79.77 million, a price-to-earnings ratio of -0.96 and a beta of 1.12.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). The business had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $1.26 million. During the same quarter last year, the business posted ($0.21) EPS. As a group, sell-side analysts anticipate that Chimerix, Inc. will post -0.86 EPS for the current year.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.